Re: INDICES> Celecoxib

[Joel Lexchin <joel.lexchin@utoronto.ca>]

Celecoxib was evaluated in the Jan. 29/99 issue of the 
Medical Letter.  The article reports on three comparative 
double blind studies:
 
1)  For OA celecoxib 100 or 200 mg bid was as effective as 
naproxen 500 mg bid.
2)  For RA celecoxib 200 or 400  mg bid was as effective 
as naproxen 500 mg bid
3)  For post surgical dental pain a single dose of 
celecoxib 100 or 200 mg  was less effective than naproxen 
500 mg or ibuprofen 400 mg.
 
 None of these trials have been published.
 
For safety:
 
Serial endoscopy studies showed that over a 12-week period 
GI ulcers occurred in 7% of patients treated with celecoxib 
200 mg bid compared to  10% with diclofenac 75 mg bid, 35% 
with naproxen 500 mg bid, 23% with ibuprofen 800 mg tid.
 
In a 24-week endoscopy study, the incidence of ulcers was 
4% with celecoxib  200 mg bid and 15% with sustained-release 
diclofenac 75 mg bid. Neither of these trials have been 
published.
 
> Joel Lexchin
> 
> 121 Walmer Rd.
> Toronto, Ontario
> CANADA M5R 2X8
> Phone:  (416)-964-7186
> Fax:  (416)-923-9515
> e mail:  joel.lexchin@utoronto.ca


--
Send mail for the `INDICES' conference to `indices@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to:  `owner-indices@usa.healthnet.org'.